January/February's product news
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
Tepezza receives marketing authorisation from MHRA
Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK
Higher Molar Dose and Its Translation into Clinical Practice
Editorial Advisory Board members bring research findings to ARVO
Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting
ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership
Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025
LuxIA receives CE-MDR certification
LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.
EMA CHMP adopts positive opinion for teprotumumab (Tepezza, Amgen) marketing authorisation application
In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment